Ozera-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying and gastroparesis. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation of Ozera-D ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. This combination is particularly beneficial in patients requiring both prokinetic and acid-suppressive therapy to manage symptoms arising from acid reflux and delayed gastric emptying. Ozera-D Capsule SR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, significant hepatic or renal impairment, or underlying cardiac conditions due to Domperidone’s potential to prolong the QT interval. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize adverse effects.